DHX58 and cancer: Finally, the use of TLR, RLR and STING modulators, to treat inflammation, auto-immune disease [227,228] and also in cancer immunotherapy [229,230,231,232,233,234,235,236] provides an eloquent incentive to continue studying these pathways and to look ahead with great optimism.